New antileishmanial quinoline linked isatin derivatives targeting DHFR-TS and PTR1: Design, synthesis, and molecular modeling studies
作者:Ahmed Sabt、Wagdy M. Eldehna、Tamer M. Ibrahim、Adnan A. Bekhit、Rasha Z. Batran
DOI:10.1016/j.ejmech.2022.114959
日期:2023.1
In a search for new drug candidates for one of the neglected tropical diseases, leishmaniasis, twenty quinoline-isatin hybrids were synthesized and tested for their in vitro antileishmanial activity against Leishmania major strain. All the synthesized compounds showed promising in vitro activity against the promastigote form in a low micromolar range (IC50 = 0.5084–5.9486 μM) superior to the reference
在寻找一种被忽视的热带疾病利什曼病的新候选药物时,合成了 20 种喹啉-靛红杂化物,并测试了它们对利什曼原虫主要菌株的体外抗利什曼原虫 活性。所有合成的化合物在低微摩尔范围内 (IC 50 = 0.5084–5.9486 μM) 均显示出优于参考米替福新 (IC 50 = 7.8976 μM) 的有前途的体外活性 。然后针对细胞内无鞭毛体形式测试所有目标化合物,并显示出有希望的抑制作用(IC 50 = 0.60442–8.2948 μM 对比米替福新 8.08 μM)。化合物4e , 4b和4f显示出对前鞭毛体和无鞭毛体形式具有最高的抗利什曼动物活性。事实证明,最活跃的化合物通过抗叶酸机制显示出显着的抗犬类动物作用,靶向 DHFR-TS 和 PTR1。为了评估最具活性的衍生物4e、4b和4f 的安全性,进行了体外细胞毒性试验并显示出比参比米替福新更高的选择性指数。假定靶蛋白 PTR1